GLP-1 SEMA | 5mg refers to a 5mg vial of Semaglutide, a potent glucagon-like peptide-1 (GLP-1) receptor agonist. While widely known by brand names like Ozempic and Wegovy, 5mg vials are frequently utilized in research or clinical settings for the management of type 2 diabetes and chronic obesity

Semaglutide functions as a “mimic” of the natural GLP-1 hormone produced in the gut. Its primary 2026 applications include: 

The 5mg format is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution

• Reconstitution: Must be dissolved with Bacteriostatic Water or sterile saline [1].
• Storage: Unopened vials should be kept in a cool, dark place. Once reconstituted, the solution must be refrigerated at 2°C to 8°C (36°F to 46°F) to maintain stability [1].
• Stability: Reconstituted Semaglutide is generally stable for up to 28 to 30 days when kept refrigerated [1]. 

Administration and Dosing 

• Method: Administered via subcutaneous injection once weekly, usually in the abdomen, thigh, or upper arm [2].
• Titration: Clinical protocols typically start at a low dose (e.g., 0.25mg) and increase monthly to minimize gastrointestinal side effects until reaching a maintenance dose [2]. 

Safety and Regulatory Status

• Side Effects: The most common effects in 2026 remain gastrointestinal, including nausea, vomiting, diarrhea, and constipation [1].
• WADA Status: Semaglutide is prohibited in competitive sports under the World Anti-Doping Agency (WADA) “S0” category for non-approved substances.
  • Precautions: It is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [2]. 
  For detailed clinical guidance, refer to the FDA Medication Guide for Wegovy or the Mayo Clinic’s overview of Semaglutide. 
  This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes